CD22 and acute lymphoblastic leukemia: Inotuzumab ozogamicin (INO), an anti-CD22 monoclonal antibody–drug conjugate (ADC), has been shown to improve remission rates and survival in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).